Jinshui Tan

Xiamen, 361004, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

METTL10-Mediated PIAS3 Methylation Links Purine Metabolism to Gastric Cancer Progression.

METTL10-Mediated PIAS3 Methylation Links Purine Metabolism to Gastric Cancer Progression.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: April 21, 2025

Transcriptional profiling reveals H.pylori-associated genes induced inflammatory cell infiltration and chemoresistance in gastric cancer.

Transcriptional profiling reveals H.pylori-associated genes induced inflammatory cell infiltration and chemoresistance in gastric cancer.

Journal: Frontiers in immunology

Published: March 12, 2025

Venetoclax confers synthetic lethality to chidamide in preclinical models with transformed follicular lymphoma.

Venetoclax confers synthetic lethality to chidamide in preclinical models with transformed follicular lymphoma.

Journal: Clinical epigenetics

Published: December 11, 2024

Activated CD38+ mast cells promote gastric cancer progression by suppressing CD8+ T cell cytotoxic activity through adenosine metabolism.

Activated CD38+ mast cells promote gastric cancer progression by suppressing CD8+ T cell cytotoxic activity through adenosine metabolism.

Journal: Cell reports

Published: December 08, 2024

Cleavage of CAD by caspase-3 determines the cancer cell fate during chemotherapy.

Cleavage of CAD by caspase-3 determines the cancer cell fate during chemotherapy.

Journal: Nature communications

Published: July 30, 2024

Dehydroabietylamine exerts antitumor effects by affecting nucleotide metabolism in gastric cancer.

Dehydroabietylamine exerts antitumor effects by affecting nucleotide metabolism in gastric cancer.

Journal: Carcinogenesis

Published: October 17, 2023

The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression.

The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression.

Journal: Scientific reports

Published: June 11, 2023

Ritanserin suppresses acute myeloid leukemia by inhibiting DGKα to downregulate phospholipase D and the Jak-Stat/MAPK pathway.

Ritanserin suppresses acute myeloid leukemia by inhibiting DGKα to downregulate phospholipase D and the Jak-Stat/MAPK pathway.

Journal: Discover oncology

Published: April 14, 2023

Anlotinib suppresses the DNA damage response by disrupting SETD1A and inducing p53-dependent apoptosis in Transformed Follicular Lymphoma.

Anlotinib suppresses the DNA damage response by disrupting SETD1A and inducing p53-dependent apoptosis in Transformed Follicular Lymphoma.

Journal: International journal of medical sciences

Published: April 04, 2023

Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway.

Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: November 15, 2022

Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.

Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.

Journal: Journal of cancer research and clinical oncology

Published: September 21, 2022

Stratification and therapeutic potential of ELL in cytogenetic normal acute myeloid leukemia.

Stratification and therapeutic potential of ELL in cytogenetic normal acute myeloid leukemia.

Journal: Gene

Published: September 11, 2022

Showing 1-12 of 17

Last Updated: 09/26/2026